



PH2 Pemigatinib in SDH-deficient GIST - PEMIGIST- Phase 2

ELIGIBILITY: Histologically confirmed SDH-deficient GIST, locally advanced or metastatic disease that is unresectable.

DRUG: Pemigatinib

SITE: Dana Farber Cancer Institute, Boston, MA



StrateGIST 3 - Phase 3

ELIGIBILITY: 18+, histologically confirmed GIST that is metastatic and/or surgically unresectable. Documented progression on, or intolerance to, first-line imatinib. Documented KIT and/or PDGFRA mutation status. KIT/PDGFR wild-type GIST, PDGFRA exon 18 mutations, and untreated or active CNS metastases are excluded.

DRUG: Velzatinib (IDRX-42) or sunitinib

SITE: US: 22 states
INT: 19 countries

StrateGIST Frontline – Phase 3

ELIGIBILITY: 18+, histologically confirmed GIST that is metastatic and/or surgically unresectable. No prior systemic therapy for metastatic/unresectable disease. ECOG ≤ 1 and at least one measurable target lesion.

DRUG: Velzatinib or imatinib

SITE: US: 12 states
INT: 15 countries



DCC-3009 - Phase 1

ELIGIBILITY: 18+, Confirmed advanced/unresectable GIST with documented KIT or PDGFRA mutations. Patients must have received at least one prior approved tyrosine kinase inhibitor in the metastatic setting.

DRUG: DCC-3009

SITE: US: 9 states

DCC-3116 - Phase 1/2

ELIGIBILITY: 18+, pathologically confirmed diagnosis of GIST with a KIT or PDGFRA mutation. Progression on at least one approved systemic regimen in the locally or metastatic setting or have documented intolerance to it. Must not have received prior ripretinib treatment.

DRUGS: Inlxisertib + ripretinib

SITE: US: 10 states (AZ, CA, FL, MA, MI, MO, NY, OH, PA, VA)
INT: 8 Countries



KQB198 – Phase 2

ELIGIBILITY: Unresectable or metastatic GIST, tissue confirmation of GIST, KIT or PDGFRA mutation (excluded: KIT Exon 9 and PDGFRA D842V). Must be in the 1st line of treatment for advanced or metastatic GIST. Prior imatinib exposure is allowed if discontinued ≥ 1 year ago.

DRUG: KQB198 + imatinib

SITE: US: 15 states (CA, FL, IL, IA, MA, MI, MN, NY, NC, OH, OR, PA, TX, UT, WA)



KOMET-015 - Phase 1

ELIGIBILITY: 18+, Advanced or metastatic KIT mutant GIST. Patients must have had progression on imatinib.

DRUG: Ziftomenib + imatinib

SITE: US: 21 states

Updated 10/15/26



MK-6482 - Phase 2

ELIGIBILITY: 12+, advanced wildtype gastrointestinal stromal tumor (wt GIST), including SDH-deficient GIST

DRUG: Belzutifan

SITE: US & International (70 global sites)



NN3201 - Phase 1

ELIGIBILITY: Confirmed advanced, metastatic, or unresectable GIST. Prior treatment with imatinib.

DRUG: NN3201 (Intravenous Drug)

SITE: US: 5 states



Expanded Access Program (EAP) to Bezuclastinib

ELIGIBILITY: 18+, confirmed advanced, metastatic, or unresectable GIST. Intolerant to imatinib or received prior imatinib therapy that resulted in disease progression. Patients with previous participation in a bezuclastinib clinical trial, intolerance to sunitinib, and known PDGFRA mutations or SDH- deficiency do not qualify.

DRUG: Bezuclastinib + sunitinib

SITE: US only



Surgery in GIST for Treatment, Tumor Modeling, and Genomic Analysis

ELIGIBILITY: 6+, confirmed GIST or clinical presentation suspicious of GIST. This is an observational study.

SITE: Bethesda, Maryland



ctDNA-Guided Sunitinib and Regorafenib Therapy for GIST - Phase 2

ELIGIBILITY: 18+, Patients who have histologically confirmed metastatic or unresectable GIST. Patients may not have received prior treatment with sunitinib or regorafenib or known to be KIT wild type.

DRUG: Sunitinib or regorafenib

SITE: Miami, Florida (can be done remotely)



Visit GISTtrials.org for more information and additional trials.